The civic record
Read. Follow. Verify.The ASAP Act: Medicare Coverage for Blood-Based Dementia Screening
Last action · November 20, 2025: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)Sponsors: Susan Collins and 49 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
The ASAP Act (S. 3267) proposes expanding Medicare coverage to include blood-based screening tests for the early detection of Alzheimer's disease and related dementias. If passed, this would allow Medicare to pay for these diagnostic tests starting in 2028.
This bill would change Medicare coverage rules to include blood-based dementia screening tests, potentially reducing out-of-pocket costs for Medicare beneficiaries seeking early detection of Alzheimer's starting January 1, 2028.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Medicare beneficiaries
Individuals enrolled in Medicare would gain access to coverage for specific blood-based dementia screening tests.
Diagnostic test manufacturers
Companies producing FDA-cleared blood-based dementia tests would be eligible for Medicare reimbursement for their products.
Key Facts
- The bill mandates Medicare coverage for blood-based early detection screening tests for Alzheimer's and related dementias.
- Coverage is scheduled to begin on January 1, 2028.
- Eligible tests must be cleared, classified, or approved by the FDA under the Federal Food, Drug, and Cosmetic Act.
- Eligible tests include genomic sequencing blood tests or other equivalent tests (including single-analyte, cell-free nucleic acids, multiplex panels, or protein expression) as determined by the Secretary of Health and Human Services.
Show all 5 facts
- The bill amends Section 1861 and Section 1833 of the Social Security Act to incorporate these tests into Medicare's payment and coverage framework.
Frequently Asked Questions
When would Medicare start covering these tests?
What kind of tests are covered?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Nov 20, 2025SenateCommitteeRead twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
- Nov 20, 2025SenateIntroducedIntroduced in Senate
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
ACADIA PHARMACEUTICALS
2026
“Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.”
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 45 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Proactive Medicare Coverage
The bill sets a specific future date (2028) for coverage, suggesting a legislative intent to prepare the Medicare system for upcoming advancements in blood-based diagnostic technology.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz25Current news / social attention level
Publisher tools